Shanghai Fosun Pharmaceutical Group Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. manufactures, distributes, and sells pharmaceutical products in Mainland China and internationally. The company offers pharmaceutical products for anti-tumor and immune modulation, metabolism and alimentary system, anti-infection, central nervous system, and cardiovascular system; and APIs and intermediates, including amino acid, tranexamic acid, le… Read more
Shanghai Fosun Pharmaceutical Group Co Ltd (600196) - Total Assets
Latest total assets as of September 2025: CN¥118.12 Billion CNY
Based on the latest financial reports, Shanghai Fosun Pharmaceutical Group Co Ltd (600196) holds total assets worth CN¥118.12 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shanghai Fosun Pharmaceutical Group Co Ltd - Total Assets Trend (1995–2024)
This chart illustrates how Shanghai Fosun Pharmaceutical Group Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shanghai Fosun Pharmaceutical Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai Fosun Pharmaceutical Group Co Ltd's total assets of CN¥118.12 Billion consist of 29.4% current assets and 70.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.5% |
| Accounts Receivable | CN¥9.43 Billion | 8.0% |
| Inventory | CN¥7.26 Billion | 6.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥19.34 Billion | 16.5% |
| Goodwill | CN¥10.91 Billion | 9.3% |
Asset Composition Trend (1995–2024)
This chart illustrates how Shanghai Fosun Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Fosun Pharmaceutical Group Co Ltd's current assets represent 29.4% of total assets in 2024, a decrease from 96.9% in 1995.
- Cash Position: Cash and equivalents constituted 11.5% of total assets in 2024, up from 6.7% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 25.0% of total assets, an increase from 0.0% in 1995.
- Asset Diversification: The largest asset category is intangible assets at 16.5% of total assets.
Shanghai Fosun Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Shanghai Fosun Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Shanghai Fosun Pharmaceutical Group Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shanghai Fosun Pharmaceutical Group Co Ltd generates 0.35x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Shanghai Fosun Pharmaceutical Group Co Ltd generates $ 2.36 in net profit.
Shanghai Fosun Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.92 | 0.92 | 1.01 |
| Quick Ratio | 0.72 | 0.72 | 0.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-2.94 Billion | CN¥ -2.99 Billion | CN¥ 212.45 Million |
Shanghai Fosun Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shanghai Fosun Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.43 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 3.5% |
| Total Assets | CN¥117.46 Billion |
| Market Capitalization | $5.78 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Fosun Pharmaceutical Group Co Ltd's assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shanghai Fosun Pharmaceutical Group Co Ltd's assets grew by 3.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shanghai Fosun Pharmaceutical Group Co Ltd (1995–2024)
The table below shows the annual total assets of Shanghai Fosun Pharmaceutical Group Co Ltd from 1995 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥117.46 Billion | +3.52% |
| 2023-12-31 | CN¥113.47 Billion | +5.88% |
| 2022-12-31 | CN¥107.16 Billion | +14.87% |
| 2021-12-31 | CN¥93.29 Billion | +11.48% |
| 2020-12-31 | CN¥83.69 Billion | +9.94% |
| 2019-12-31 | CN¥76.12 Billion | +7.89% |
| 2018-12-31 | CN¥70.55 Billion | +13.85% |
| 2017-12-31 | CN¥61.97 Billion | +41.59% |
| 2016-12-31 | CN¥43.77 Billion | +14.57% |
| 2015-12-31 | CN¥38.20 Billion | +8.11% |
| 2014-12-31 | CN¥35.34 Billion | +19.88% |
| 2013-12-31 | CN¥29.48 Billion | +15.56% |
| 2012-12-31 | CN¥25.51 Billion | +14.43% |
| 2011-12-31 | CN¥22.29 Billion | +32.52% |
| 2010-12-31 | CN¥16.82 Billion | +45.92% |
| 2009-12-31 | CN¥11.53 Billion | +52.90% |
| 2008-12-31 | CN¥7.54 Billion | +1.40% |
| 2007-12-31 | CN¥7.43 Billion | +12.08% |
| 2006-12-31 | CN¥6.63 Billion | +17.03% |
| 2005-12-31 | CN¥5.67 Billion | +9.64% |
| 2004-12-31 | CN¥5.17 Billion | +22.56% |
| 2003-12-31 | CN¥4.22 Billion | +34.38% |
| 2002-12-31 | CN¥3.14 Billion | +42.23% |
| 2001-12-31 | CN¥2.21 Billion | +40.50% |
| 2000-12-31 | CN¥1.57 Billion | +83.06% |
| 1999-12-31 | CN¥858.23 Million | +32.62% |
| 1998-12-31 | CN¥647.14 Million | +125.38% |
| 1997-12-31 | CN¥287.13 Million | +158.00% |
| 1996-12-31 | CN¥111.29 Million | +4.31% |
| 1995-12-31 | CN¥106.70 Million | -- |